Company intelligence / Profile preview

Syte Bio

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Syte Bio is a synthetic biology company focused on developing programmable live biotherapeutic products (LBPs) for the treatment of gastrointestinal and systemic diseases. The company leverages a proprietary platform to engineer bacteria that can sense specific disease biomarkers in the gut and respond by producing therapeutic molecules locally. By creating these "smart" microbes, Syte Bio aims to provide highly targeted, responsive treatments that minimize systemic side effects while maximizing efficacy in the gut environment. Their initial focus is on inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

Therapeutic areas: Gastroenterology
Modalities: Live biotherapeutic product therapyBiologicMicrobial therapy
Industry: Biotech

Drug pipeline

1 asset

anti-PD-L1 (human)

Preclinical

Beyond the preview

Go deeper on Syte Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syte Bio.

Explore the full profile